A Phase 1B/2, Open-Label, Safety And Efficacy Study Of Epcoritamab (Gen3013; Duobody®-Cd3 X Cd20) In Relapsed/Refractory Chronic Lymphocytic Leukemia And Richter’S Syndrome
Posted Date: May 19, 2025
- Investigator: John Byrd
- Specialties: Leukemia, Lymphoma
- Type of Study: Drug
This trial focuses on administering Epcoritamab in Relapsed and Refractory CLL or Richter's either as monotherapy or together with other targeted agents.
Criteria:
Relapsed And Refractory Cll Or Ricther's Transformation
Keywords:
Chronic Lymphocytic Leukemia, Clinical Trial, Richter's Transformation
For More Information:
John C. Byrd
NULL
byrd2jc@ucmail.uc.edu